Mecklenburg Gabriel M.I. sold $3.3M of HNGE

Mecklenburg Gabriel M.I. sold 50,000 shares of Hinge Health, Inc. (HNGE) at an average of $65.54 ($65.53–$66.00, $3.28M total) across 2 trades on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mecklenburg Gabriel M.I.
Published Jun 6, 2026, 12:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Bearish
medium confidence
Mentioned
$HNGE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGEBearishLow
01

Why it matters

The filing provides fresh, material information about insider sentiment, which can influence short‑term price action.

02

Market read

Direct insider sell of $3.3M may trigger short‑term downside pressure on HNGE.

03

What to watch

Potential upcoming financing round or strategic shift could motivate the exit.

Relevance 5/10Novelty 6/10Timing: pre‑market

Background

SEC Form 4 filing discloses a director's complete exit from Hinge Health shares under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$HNGEBearishMedium confidence
Context

Director Mecklenburg Gabriel sold 50,000 shares for $3.3M via a 10b5‑1 plan, reducing holdings to zero.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A director exiting completely suggests reduced confidence; the $3.3M size is material for a mid‑cap.

Market effects

Minimal impact on the broader digital health sector; isolated insider activity.

Limited to U.S. investors tracking Hinge Health.

None

Counterpoint

The sale may be a routine liquidity event unrelated to fundamentals.

Key entities

  • Mecklenburg Gabriel

    Insider who sold all holdings in Hinge Health.

  • Hinge Health, Inc.

    Digital health company whose stock is affected by the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Needham raises Hinge Health stock price target on client growth

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

$HNGEHighAI 8/10

Hinge Health (HNGE) Q3 2026 Earnings Call Transcript

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.